Another study identified R-carvedilol, the enantiomer without β-blocking activity, as a potential mediator of cancer-preventive activity, since it successfully stimulates the RAS-RAF-MEK-MAPK pathway, without leading to ELK1 activation [264]. This evidence concerns the gene ELK1 and cancer.